Antimicrobial resistance is a critical global health challenge, threatening the effectiveness of modern medicine and increasing the risk of untreatable infections. In Australia, recent policy reviews have highlighted the need for a pilot subscription funding model to enable accessibility to new and novel antimicrobials, and to incentivise their development. 

In response an Antimicrobial Subscription Model roundtable was convened on 18 November 2024, made up of 35 leaders in infectious disease management, from government, research, clinical practice and industry. Its goal was to develop a consensus on the design and implementation of an Australian pilot program. In part this roundtable drew on insights from global examples, particularly the recent experience of the United Kingdom. 

This report summarises discussion at the roundtable. The roundtable agreed on 10 key principles to guide the development of a pilot subscription payment model for novel antimicrobials and its implementation in Australia.